内镜黏膜下剥离术治疗浅表环周食管鳞状细胞癌的临床结局
回顾性分析2009至2020年52例因浅表环周食管鳞状细胞癌接受内镜黏膜下剥离术(ESD)的患者,整块切除率100%,R0切除率69.2%,中位手术时间112分钟,术中穿孔4例(7.7%),迟发出血1例(1.9%);中位随访49.1个月,4年总生存率86.2%、疾病特异性生存率95.5%、累积复发率11.5%,低风险患者长期结局良好。
要点
- 52例浅表环周食管鳞癌ESD整块切除率100%,R0切除率69.2%。
- 中位随访49.1个月,4年总生存率86.2%、疾病特异性生存率95.5%、累积复发率11.5%。
- 低风险患者(pT1a、脉管侵犯阴性、垂直切缘阴性)单独ESD后4年总生存率93.2%、疾病特异性生存率100%、累积复发率0%。
核心结论
- ESD是浅表环周食管鳞状细胞癌的高度根治性治疗,长期结局良好,尤其在低风险患者中。
- 应改进狭窄预防技术以优化ESD对浅表环周食管鳞状细胞癌的获益。
研究设计与样本
- 回顾性纳入2009年至2020年连续接受ESD治疗的浅表环周食管鳞状细胞癌患者,共52例52处病变。
- 短期结局包括整块切除、R0切除、手术时间和不良事件;长期结局包括总生存(OS)、疾病特异性生存(DSS)、累积复发率(CRR)和临床病程。
主要发现
- 中位肿瘤长度5.0 cm(四分位距[IQR] 4.0-6.3)。
- 整块切除率100%(95%CI 94.4-100),R0切除率69.2%(95%CI 54.9-81.3)。
- 中位手术时间112分钟(IQR 87-162),术中穿孔4例(7.7%),迟发出血1例(1.9%)。
- 42例仅接受ESD治疗的患者中36例(85.7%)发生食管狭窄。
- 中位随访49.1个月(IQR 25.7-74.7)时,4年OS 86.2%(95%CI 71.6-93.6)、DSS 95.5%(95%CI 83.1-98.9)、CRR 11.5%(95%CI 4.1-23.1)。
关键数值与推荐
- 低风险cESCC定义为pT1a、脉管侵犯阴性且垂直切缘阴性。
- 低风险与高风险病变患者OS无显著差异(P=0.93),无论是否接受额外治疗。
- 31例低风险cESCC仅接受ESD治疗者,4年OS 93.2%、DSS 100%、CRR 0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Our aim was to elucidate the clinical outcomes of endoscopic submucosal dissection (ESD) for superficial circumferential esophageal squamous cell carcinoma (cESCC). METHODS: Consecutive patients who underwent ESD for cESCC between 2009 and 2020 were retrospectively reviewed. Short-term outcomes were en-bloc resection, R0 resection, procedure time, and adverse events, whereas long-term outcomes were overall survival (OS), disease-specific survival (DSS), cumulative recurrence rate (CRR), and clinical course. RESULTS: Fifty-two patients with 52 cESCCs (median tumor length, 5.0 cm; interquartile range [IQR], 4.0-6.3) were evaluated. The en-bloc resection and R0 resection rates were 100% (95% confidence interval [CI], 94.4-100) and 69.2% (95% CI, 54.9-81.3), respectively. The median procedure time was 112 minutes (IQR, 87-162). Intraoperative perforations and delayed bleeding occurred in 4 (7.7%) and 1 (1.9%) patients, respectively. Among the 42 patients who underwent ESD alone, 36 (85.7%) experienced esophageal strictures. Within a median follow-up of 49.1 months (IQR, 25.7-74.7), the 4-year OS, DSS, and CRR were 86.2% (95% CI, 71.6-93.6), 95.5% (95% CI, 83.1-98.9), and 11.5% (95% CI, 4.1-23.1), respectively. There was no significant difference in the OS between patients with low-risk cESCC (pT1a, negative lymphovascular invasion, and negative vertical margin) and high-risk lesions, regardless of undergoing additional treatment (P = .93). In 31 patients with low-risk cESCC who were treated with ESD alone, the 4-year OS, DSS, and CRR were 93.2%, 100%, and 0%, respectively. CONCLUSIONS: ESD is a highly curative treatment for cESCC with favorable long-term outcomes, especially in low-risk patients. Stricture-prevention techniques should be improved to optimize the benefits of ESD for cESCC.
引用
- Minamide T, Kawata N, Maeda Y, et al. Clinical outcomes of endoscopic submucosal dissection for superficial circumferential esophageal squamous cell carcinoma. Gastrointest Endosc. 2022. PMID: 36228694. doi:10.1016/j.gie.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。